RCEL insider trading
NasdaqCM HealthcareAVITA Medical, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About AVITA Medical, Inc.
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
Company website: avitamedical.com
RCEL insider activity at a glance
FilingIQ has scored 115 insider transactions for RCEL since Jul 16, 2020. The most recent filing in our index is dated Mar 11, 2026.
Across the full history, 36 open-market purchases
and 13 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on RCEL insider trades is 53.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
13F funds holding RCEL
Frequently asked
- How many insider trades does FilingIQ track for RCEL?
- FilingIQ tracks 115 Form 4 insider transactions for RCEL (AVITA Medical, Inc.), covering filings from Jul 16, 2020 onwards. 6 of those were filed in the last 90 days.
- Are RCEL insiders net buyers or net sellers?
- Across the full Form 4 history for RCEL, 36 transactions (31%) were open-market purchases and 13 (11%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does RCEL insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is RCEL in?
- AVITA Medical, Inc. (RCEL) is classified in the Healthcare sector, specifically Medical Devices, with a current market capitalisation of $179.58M.
Methodology & sources
Every RCEL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.